XENE
HEALTHCAREXenon Pharmaceuticals Inc
$58.59+0.88 (+1.52%)LIVE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving XENE Today?
No stock-specific AI insight has been generated for XENE yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$28.19$63.95
$58.59
Fundamentals
Market Cap$5.7B
P/E Ratio—
EPS$-4.36
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin—
Debt / Equity—
Trading
Volume724K
Avg Volume (10D)—
Shares Outstanding96.6M
XENE News
20 articles- Xenon Q1 Earnings Match Estimates, Pipeline Development in FocusYahoo Finance·May 8, 2026
- Xenon (XENE) Q1 2026 Earnings TranscriptMotley Fool·May 7, 2026
- Xenon Reports Q1 2026 Financial Results and Provides Business UpdateYahoo Finance·May 7, 2026
- X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue EstimatesYahoo Finance·May 6, 2026
- Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·May 1, 2026
- Three Finalists Announced for the 2026 Bloom Burton AwardYahoo Finance·May 1, 2026
- Xenon to Report Q1 2026 Financial Results on May 7, 2026Yahoo Finance·Apr 30, 2026
- KCNQ2 Developmental and Epileptic Encephalopathy Market Research Report 2025-2035, Competitive Analysis of Biohaven, Xenon Pharma, Lundbeck, Praxis Precision Medicines, NeuShen TherapeuticsYahoo Finance·Apr 28, 2026
- Xenon Pharmaceuticals Highlights Strong Phase III Azetukalner Data, Q3 NDA Plans at Bloom Burton ConferenceMarketbeat·Apr 26, 2026
- Xenon Pharmaceuticals Inc (XENE) Looking At a $2 Billion Opportunity HereYahoo Finance·Apr 23, 2026
- Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual MeetingGlobeNewswire Inc.·Apr 19, 2026
- Xenon to Present at Upcoming Investor ConferencesYahoo Finance·Apr 15, 2026
- Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual MeetingYahoo Finance·Apr 7, 2026
- Xenon Pharma Stock Up 55% as Insider Sells $78K in Shares. Here's What Investors Should KnowThe Motley Fool·Mar 27, 2026
- Xenon Pharmaceuticals Stock Soars 20% in 3 Months: Here's WhyYahoo Finance·Mar 19, 2026
- Xenon Pharmaceuticals (XENE) Is Down 6.7% After $650 Million Follow-On Offering And Phase 3 Epilepsy WinYahoo Finance·Mar 18, 2026
- Xenon Pharmaceuticals (XENE) Climbs 31.7% as Epilepsy Treatment Moves ForwardYahoo Finance·Mar 15, 2026
- This Fund Has a $200 Million Bet on a Biotech Stock Up 30% in Days After Phase 3 BreakthroughMotley Fool·Mar 13, 2026
- Battery Storage Stock Up 50% in a Year Draws New $110M Investment. Here's What You Should KnowMotley Fool·Mar 13, 2026
- Biotech Stock Up 685% Draws $80.5 Million Investment Amid Dual FDA FilingsMotley Fool·Mar 13, 2026
All 20 articles loaded
Price Data
Open$56.39
Previous Close$57.71
Day High$57.89
Day Low$55.98
52 Week High$63.95
52 Week Low$28.19
52-Week Range
$28.19$63.95
$58.59
Fundamentals
Market Cap$5.7B
P/E Ratio—
EPS$-4.36
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin—
Debt / Equity—
Trading
Volume724K
Avg Volume (10D)—
Shares Outstanding96.6M
About Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies to treat patients with neurological disorders in Canada. The company is headquartered in Burnaby, Canada.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—